Reich DE, Lander ES. On the allelic spectrum of human disease. Trends Genet. 2001;17(9):502-10.
Hayes TK, Luo F, Cohen O, et al. A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma. Cancer Res. 2019;79(9):2352-2366. doi:10.1158/0008-5472.CAN-18-2711
Marini S, Anderson CD, Rosand J. Genetics of Cerebral Small Vessel Disease. Stroke. 2020;51(1):12-20. doi:10.1161/STROKEAHA.119.024151
Ellrott K, Bailey MH, Saksena G, et al. Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018;6(3):271-281.e7. doi:10.1016/j.cels.2018.03.002
Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018;8(6):714-729. doi:10.1158/2159-8290.CD-17-1256
Garvie CW, Wu X, Papanastasiou M, et al. Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase. Nat Commun. 2021;12(1):4375. doi:10.1038/s41467-021-24495-w
Martins MM, Zhou AY, Corella A, et al. Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov. 2015;5(2):154-67. doi:10.1158/2159-8290.CD-14-0552
Khera AV, Won HH, Peloso GM, et al. Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease. JAMA. 2017;317(9):937-946. doi:10.1001/jama.2017.0972
Bi WL, Greenwald NF, Ramkissoon SH, et al. Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. Endocrinology. 2017;158(7):2284-2291. doi:10.1210/en.2016-1967
Emdin CA, Khera AV, Klarin D, et al. Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling. Circulation. 2018;137(3):222-232. doi:10.1161/CIRCULATIONAHA.117.028021